London, Jan. 30, 2024 (GLOBE NEWSWIRE) -- January 30, 2024, London, UK – OPEN Health has launched OPEN X Health , a new practice focused on providing data-driven creativity to the pharmaceutical industry. OPEN X Health (OPEN X) ...
In the Phase 2b trial, 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection Further analyses will be forthcoming as data become ...
- SION-109 is a small molecule targeting the interface between the ICL4 region and the NBD1 domain of the CFTR protein; designed to complement the company's NBD1 modulator portfolio - - First subject dosed in Phase 1 clinical trial - ...
HANGZHOU and SHAOXING, China , Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to ...
NEW TAIPEI CITY , Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for ...
PARAMUS, N.J. , Jan. 22, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being developed ...
Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial ...
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January , 2024 - Orphalan SA (“Orphalan” or “the Company”), an international orphan drug ...
Treatment with IPL344 was well tolerated Changes in the slope of decline in ALSFRS-R demonstrated 48% slower disease progression (p=0.028); and 64% slower progression when adjusted for disease stage and rate (p=0.034) Study suggests benefits ...
GUANGZHOU, China , Jan. 10, 2024 /PRNewswire/ -- Guangzhou Fermion Technology Co., Ltd. (Fermion), a clinical-stage AI-based drug discovery company that specializes in developing drugs for autoimmune diseases and pain, has announced today ...
Researchers at the Indian Institute of Technology (IIT) Guwahati disclosed the technology transfer for India's inaugural recombinant vaccine against the swine fever virus, facilitating its commercial deployment in pigs and wild boars ...
Perrigo’s announcement of Opill (norgestrel) ( ) becoming available over-the-counter marks a milestone as the first daily birth control pill to do so in the US. Opill Promises Expanded Over-the-Counter Oral Contraceptive ...
The rise of GLP-1 agonist drugs, including Ozempic and Wegovy, has reshaped the weight loss and diabetes treatment landscape in 2023. Fueled by promising clinical trial results and...
Ebola virus disease (EVD), caused by several species of viruses belonging to the genus Ebolavirus , is a severe and often fatal illness in humans. It is characterized by symptoms such as fever , severe vomiting, bleeding, and neurological issues. EVD ...
On March 14, 2024, the FDA announced its accelerated approval of Resmetirom for the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is commonly referred as Non-alcoholic steatohepatitis (NASH). It can be prescribed ...
Subscribe to our Free Newsletters!